|
|
Vol. 10.08 – 18 March, 2024
|
|
|
|
|
|
|
|
Investigators showed that HAPLN1 in the dermal extracellular matrix was sufficient to maintain the integrity of melanoma-associated blood vessels, as indicated by increased collagen and VE-cadherin expression. [Nature Aging]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
DERMAL STEM CELLS & TISSUE REGENERATION
|
|
|
|
|
|
In a 3D organotypic human epidermis model, loss of dolichyl-phosphate mannosyltransferase subunit 1 (DPM1) caused impaired differentiation with abnormally increased cornification, reduced thickness of non-corneal layers, and formation of intercellular gaps in the epidermis.
[Journal Of Cell Biology]
|
|
|
|
|
|
Scientists demonstrated that after SPRY1 knockout in epidermal keratinocytes, melanocyte stem cells in the hair follicle exit the niche without depleting the pool of these cells.
[Journal Of Investigative Dermatology]
|
|
|
|
|
|
Researchers employed qRT-PCR and fluorescence in situ hybridization to evaluate miR-6785-5p in psoriatic keratinocytes and conducted a microRNA microarray for identifying differentially expressed miRNAs in patient serum exosomes.
[Inflammation]
|
|
|
|
|
|
|
|
The authors showed that miR-579-3p was specifically deregulated in BRAF-mutant melanomas and that its expression levels mirrored those of microphthalmia-associated transcription factor (MITF). [Cell Death & Disease]
|
|
|
|
|
|
Investigators explored extracellular galectin-3 expression in human melanoma tissues as well as murine melanoma models to examine its causal role in metastatic behavior. [Journal Of Investigative Dermatology]
|
|
|
|
|
|
|
|
|
The authors discuss research progress on lipid metabolism in melanoma, and emphasize the dynamic ability of metabolism during tumorigenesis as a target for improving response to different therapies and for overcoming drug resistance in melanoma. [Biochemical Pharmacology]
|
|
|
|
|
|
|
|
A team of investigators from the UCLA Health and the University of Arkansas as awarded a $3.2 million grant from the National Institutes of Health to identify new ways to prevent and overcome treatment resistance to targeted therapy in patients with all sub-types of cutaneous melanoma. [UCLA Health]
|
|
|
|
|
|
|
|
April 24 – 26, 2024 Vienna, Austria
|
|
|
|
|
|
|
|
|
|
|
abbvie – Irvine, California, United States
|
|
|
|
|
|
|
University of Texas Southwestern Medical Center – Dallas, Texas, United States
|
|
|
|
|
|
|
Office of Women’s Health Grant Program – Jefferson, Arkansas, United States
|
|
|
|
|
|
|
UC Davis – Davis, California, United States
|
|
|
|
|
|
|
Brown University – Providence, Rhode Island, United States
|
|
|
|
|
|